Lijin Li

Dr. Lijin Li

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2026 in Nature
Verified
Journal Article
Closed access
PDF file
SJSuin Jo
Suin Jo
LLLijin Li
Lijin Li
CTChandrani Thakur
Chandrani Thakur
KTKevin A. Telfer
Kevin A. Telfer
HSHussein Sultan
Hussein Sultan
KMKenneth M. Murphy
Kenneth M. Murphy

30 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MCMichael Chen
Michael Chen
TKThomas Kane
Thomas Kane
ICIna Chen
Ina Chen
SSSuangson Supabphol
Suangson Supabphol
XZXiuli Zhang
Xiuli Zhang
WGWilliam E. Gillanders
William E. Gillanders
Background: Personalized cancer vaccines (PCVs) are a promising form of cancer immunotherapy, capable of eliciting robust neoantigen-specific immune responses. However, cancer neoantigens are variable in terms of immunogenicity, and PCVs may be less effective when targeting weak neoantigens. Strong and durable immune responses are also likely to be critical for vaccine efficacy. Interleukin-7 (IL-7) is a common gamma-chain cytokine known to support T cell development and survival, and a long-acting form of recombinant human IL-7 fused with hybrid Fc (rhIL-7-hyFc) has shown potential to enhance immune responses in early-stage clinical trials. Methods: In this study, we evaluated the ability of rhIL-7-hyFc to serve as a molecular adjuvant to a DNA PCV in the E0771 murine breast cancer model. Results: We found that the combination of rhIL-7-hyFc and DNA PCV treatment prolonged neoantigen-specific CD8+ T cell responses, improved functional memory as measured based on in vivo cytotoxicity, and increased the number of neoantigen-specific tumor-infiltrating lymphocytes (TILs), resulting in improved prophylactic tumor protection and durable memory responses. Conclusions: Our findings support the potential of rhIL-7-hyFc to enhance the efficacy of PCVs and suggest clinical utility for adjuvant rhIL-7-hyFc in cancer immunotherapy.

6 February 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in >50% of patients with breast cancer. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients with stable metastatic disease. To further evaluate the potential of the Mam-A vaccine, we initiated a phase Ib clinical trial in patients with estrogen receptor–positive breast cancer prior to surgery. Eight patients were assigned to arm 1 (neoadjuvant endocrine therapy alone) and 17 to arm 2 (neoadjuvant endocrine therapy plus Mam-A vaccination); the final analysis included 8 patients from arm 1 and 13 from arm 2. Ex vivo enzyme-linked immunospot (ELISpot) analysis of peripheral blood mononuclear cells demonstrated that Mam-A vaccination induced Mam-A–specific T cells in 8 of 13 patients. Intracellular cytokine staining and Mam-A–specific tetramer staining revealed that vaccine-induced Mam-A–specific T cells included both CD4+ and CD8+ polyfunctional T cells. Finally, high-throughput imaging mass cytometry identified 24 cellular metaclusters with features of tumor, immune, stromal, and endothelial cells and revealed an increased CD8+ T-cell prevalence in the tumor after Mam-A vaccination. In particular, vaccination was associated with the infiltration of PD-1+CD8+ T cells. In addition, postvaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.


2 April 2026
Verified
Other
Open access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
Amino acid sequence and HLA specificity of Mam-A peptides used for ICS and tetramer analysis